FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:98-99 July 2, 2009 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We recently found that progression-free survival was shorter among patients with metastatic colorectal cancer treated with chemotherapy, bevacizumab, and cetuximab (CBC regimen) than among patients who received chemotherapy and bevacizumab alone (CB regimen) (Feb. 5 issue).¹ Other investigators have found that the efficacy of cetuximab is limited to patients with wild-type–KRAS tumors.² In a subgroup of 520 patients with available tumor samples, we observed a shorter median progression-free survival among patients with a mutated-KRAS oncogene in the CBC group than among patients with mutated-KRAS tumors who received the CB regimen and among patients with . . . [Full Text of this Article]

This article has been cited by other articles:

• Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., Bardelli, A. (2009). Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. JNCI J Natl Cancer Inst 101: 1308-1324 [Abstract] [Full Text]